Tranquis Therapeutics, a San Mateo, Calif.-based private immuno-neurology company, raised $30m in Series A funding.
The round was co-led by Remiges Ventures and SR One, with participation from Vivo Capital, Hillsborough Venture, Correlation Ventures and other investors.
The company intends to use the funds to complete the non-clinical development work for its pipeline program, TQS-168, and advance it toward clinical proof of concept in orphan diseases such as ALS or FTD, while further expanding the discovery platform and pipeline with next generation compounds.
Led by Sanjay Kakkar, MD, MSc, MPH, President and CEO, and Titus Plattel, MSc, MBA, Chief Business Officer, Tranquis Therapeutics is discovering and developing a portfolio of small molecules which cross the blood-brain barrier. The company is initially focusing development in orphan diseases including ALS and FTD, with the TQS-168 program currently in preclinical development. In addition, Tranquis is developing a second generation of compounds from the TQS-168 platform targeting more prevalent diseases such as PD, AD and age-related pathologies.
The company’s novel therapeutic approach stems from research at the Stanford laboratory of Professor Edgar Engleman, MD, Tranquis’ scientific founder, which indicates that myeloid immune cell dysfunction underlies a variety of nervous system disorders such as Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s Disease (PD), Alzheimer’s Disease (AD), and age-related neuropathology.